Leading Clinical Ultrasound AI Company Shizhijue Completes Tens of Millions RMB Financing Round

On October 30, 2024, SHIZHIJUE (hereinafter referred to as “SHIZHIJUE” or the “Company”), a leading enterprise in clinical ultrasound AI, announced the completion of a new round of financing amounting to tens of millions of yuan, with Yishang Huicheng Investment Fund (hereinafter referred to as “Yishang Huicheng”). This round of financing reflects the high level of attention paid by specialized healthcare investment institutions to the trend of AI-enabled ultrasound entering clinical departments, as well as their strong recognition of the SHIZHIJUE management team.RCCAPITALServed as the exclusive financial advisor for SHIZHIJUE’s financing and continued to be responsible for subsequent fundraising.

— SHIZHIJUE —

SHIZHIJUE is dedicated to providing one-stop artificial intelligence solutions for ultrasound-based diagnosis and treatment, serving as a pioneer in the field of clinical ultrasound AI. The company adheres toMed-Intelligence FusionGuided by medical experts from the Musculoskeletal and Superficial Ultrasound Professional Committee of the Chinese Research Hospital Association, with intelligent technology specialists from the Institute of Automation, Chinese Academy of Sciences at its core, and supported by numerous top-tier Grade A tertiary hospitals, we have successfully developed a real-time dynamic AI-assisted diagnostic and therapeutic system for musculoskeletal ultrasound. This system achieves real-time dynamic segmentation of multiple tissues, effectively transforming in vivo anatomical information required for clinical treatments in pain management, anesthesiology, rehabilitation, and traditional Chinese medicine into intuitive, user-friendly, structured visual data.

SHIZHIJUE's AI-Assisted Real-Time Dynamic Musculoskeletal Ultrasound Diagnostic and Therapeutic System, forClinicians Adopt Ultrasound, and Sonographers Move Toward Clinical PracticeProvides visualization of fine living anatomy (six major joints) and assists in precise diagnosis and treatment. This will significantly shorten the clinical learning curve and improve physicians' work efficiency. This system enablesVisualized Pain (Anesthesia), Quantifiable Rehabilitation, Minimally Invasive Surgery, and Refined Internal MedicineMoreover, the emergence of wearable ultrasound and home-based ultrasound systems has become possible, holding significant importance.

— Core Products —

SHIZHIJUE boasts a stellar founding team. Mr. Zhang Chen, the Chairman of the Board, previously served as the Head of Sales at an AI healthcare unicorn company, where he expanded business to over 300 Grade A tertiary hospitals. Dr. Guo Ruijun, Chief Medical Officer and former Director of the Department of Ultrasound Medicine at Beijing Chaoyang Hospital, currently serves as the Chairperson of the Musculoskeletal and Superficial Ultrasound Professional Committee of the Chinese Research Hospital Association. Mr. Jiang Yongshi, Chief Executive Officer, is a renowned expert in graphics, image processing, and artificial intelligence. He formerly held the position of Senior Research Fellow at the Institute of Automation, Chinese Academy of Sciences, and was awarded the First Prize for Scientific and Technological Progress by the People's Liberation Army. Additionally, Mr. Yang Yiping, former Deputy Director of the Institute of Automation, Chinese Academy of Sciences, serves as a member of the company’s Board of Directors.

— Core Team —

SHIZHIJUE, established on May 31, 2023, has demonstrated exceptional execution under the leadership of its seasoned team: within just a few months of incorporation, it secured its first round of investment from TusStar; product development was completed within six months, followed by initial clinical trials in hospitals; commercialization and revenue generation were achieved within one year, with deployment expanding to approximately 50 authoritative hospitals. Now, only 16 months after its founding, the company has successfully closed its Series B financing led by Yishang Huicheng (Beijing) Investment Management Co., Ltd. Such efficiency is particularly valuable in today’s stringent market environment.

— Efficacy of Adjuvant Therapy —

— Product Presentation —

Regarding this round of financing, Mr. Zhang Chen, Chairman of SHIZHIJUEIndicate: We extend our gratitude to Yishang Huicheng (Beijing) Investment Management Co., Ltd. for their choice and trust in our company, as well as for their efficient collaboration during this period. We also thank RCCAPITAL for their professional services throughout the entire process. With five years of experience in selling medical AI products, I have identified musculoskeletal ultrasound as a significant market opportunity. While it is widely acknowledged that the integration of ultrasound into clinical departments is a major trend, a closer examination reveals that departments such as pain management, anesthesiology, emergency medicine, rehabilitation, and traditional Chinese medicine have a primary demand for musculoskeletal ultrasound. Meanwhile, there is a scarce number of clinicians proficient in interpreting and applying musculoskeletal ultrasound for disease diagnosis and treatment. AI-powered musculoskeletal ultrasound products genuinely empower multiple departments to conduct ultrasound-guided diagnosis and therapy. Our rapid penetration into numerous departments during promotion further corroborates the widespread and essential nature of this clinical need. Following this financing round, we will further expand our product module layout, accelerate market publicity and hospital adoption, strengthen collaborations with high-quality resources across all parties, and further solidify our leading position in the field of musculoskeletal ultrasound AI.

As the investor, Yishang Huicheng Investment TeamIndicates: Ultrasound equipment offers the advantages of being lightweight, flexible, and radiation-free. We have long monitored the trend of ultrasound applications in outpatient departments, and SHIZHIJUE has precisely capitalized on this trend, boasting immense future potential. Meanwhile, SHIZHIJUE’s business model features exceptionally high entry barriers. First, top-tier physicians in the field of musculoskeletal ultrasound are scarce, and the number of leading hospitals is limited; products endorsed by them possess irreplicable academic authority. Second, data acquisition and model training form a closed loop: high-quality data is essential for training robust models, and robust models are prerequisite to acquiring high-quality data. This positive feedback mechanism makes it extremely difficult for competitors to enter the field. Although SHIZHIJUE was established just over a year ago, under the leadership of Mr. Zhang Chen, the team has demonstrated strong execution capabilities. The product has undergone multiple iterations, and its performance and market promotion have already positioned it as an industry leader.

As the exclusive financial advisor, Ms. Yan Guopei, Head of RCCAPITAL’s Northern Region, stated: The musculoskeletal ultrasound AI sector selected by SHIZHIJUE addresses the urgent need for ultrasound equipment to enter clinical departments, enabling widespread empowerment of the hundreds of thousands of installed ultrasound units across various departments, representing a market space valued in the tens of billions. Meanwhile, the company’s product R&D and registration progress are industry-leading, supported by a comprehensive team whose dedication is admirable. In particular, we have strong confidence in the team: we are optimistic about Chairman Mr. Zhang Chen’s capabilities in hospital expansion and sales; about Director Guo Ruijun, an authority in musculoskeletal ultrasound, for his clinical and product oversight; and about CEO Researcher Jiang Yongshi for his profound expertise in AI technology, algorithm iteration, and product development, backed by robust AI capabilities originating from the Institute of Automation, Chinese Academy of Sciences. SHIZHIJUE’s team is a powerful combination with no weaknesses, providing strong support for achieving the company’s various milestones. We remain firmly confident in SHIZHIJUE’s development and will provide long-term support as it grows.

Beijing SHIZHIJUE Intelligent Technology Co., Ltd. is a medical technology company focused on AI-enabled medical ultrasound, dedicated to promoting the widespread application of ultrasound equipment in clinical departments, with a current focus on the field of musculoskeletal ultrasound. SHIZHIJUE features real-time dynamic segmentation of multiple tissues as its product hallmark and leverages low latency as its technical advantage, filling the gap in AI-assisted real-time dynamic anatomy for musculoskeletal ultrasound. The company’s products effectively address clinical pain points, such as clinicians’ unfamiliarity with ultrasound images in outpatient settings, the lengthy learning curve for muscle anatomy under ultrasound, and the difficulty in locating similar imaging planes. Currently, SHIZHIJUE has completed the development of modules for the wrist, knee, and shoulder, and will sequentially develop teaching modules, common disease diagnosis modules, and precise treatment modules for the six major joints and peripheral nerves, thereby comprehensively meeting clinical application needs.

Yishang Huicheng (Beijing) Investment Management Co., Ltd. is a venture capital fund that makes equity investments in technologically innovative companies within China’s biopharmaceutical sector. Jointly established by well-known listed pharmaceutical companies and government industrial guidance funds, the fund focuses on investing in new drug development, novel biotechnological therapies, and new drug R&D service organizations. Yishang Huicheng is committed to seizing industry opportunities and pooling professional expertise, facilitating corporate partnerships through resource integration and empowering enterprises to achieve mutual growth through strategic investment.

RCCAPITAL is a boutique investment bank specializing in the healthcare and medical sector, with offices in Beijing, Shanghai, and Hangzhou. It is renowned in the industry for its high efficiency, high success rate, and comprehensive services. The RCCAPITAL team comprises professionals from boutique investment banks, accounting firms, biotechnology companies, and other related fields. Since its establishment, the firm has facilitated cumulative financing amounts totaling billions of RMB for its clients, covering sectors such as diagnostics, medical devices, digital health, biotechnology, new drug R&D, healthcare services, innovative payment solutions, CXO, and general wellness.